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500Background: Redo aortic valve replacement procedures have been reduced by the growing practice of
trans-catheter aortic valve-in-valve procedures. We analyzed our long-term results of redo aortic valve
replacement procedures during a 10-year period in an effort to define subgroups in which trans-catheter aortic
valve-in-valve procedures may be better than surgery.
Methods: From 2002 to 2010, 131 redo aortic valve replacement procedures with at least 18 months of
follow-up were prospectively enrolled. Hospital and follow-up outcome of the entire population and of
high-risk subgroups were evaluated.
Results: Hospital mortality was 2.3%, major re-entry complications were seen in 1.5%, re-exploration for
bleeding was seen in 9.2%, perioperative low cardiac output state (ie, low cardiac output syndrome) was
seen in 9.9%, stroke was seen in 3.1%, prolonged ventilation was seen in 18.3%, pneumonia was seen in
4.6%, acute renal insufficiency was seen in 11.5%, intra-aortic counterpulsation (intra-aortic balloon pump)
was seen in 9.2%, renal replacement therapy was seen in 4.6%, need for transfusions was seen in 60.3%,
and permanent pacemaker implantation was seen in 2.3%. One hundred twenty-month actuarial survival,
freedom from acute heart failure, reinterventions, stroke, and thromboembolisms were 61.5%  8.6%,
62.9%  6.9%, 97.8%  1.5%, 93.2%  3.0%, and 91.2%  3.2%, respectively. Patients aged>75 years
had similar outcome to younger patients (nonsignificant P for all). Endocarditis resulted in higher hospital
mortality (P ¼ .034), low cardiac output state (P<.0001), intra-aortic balloon pump (P<.0001), prolonged
ventilation (P ¼ .011), pneumonia (P ¼ .049), acute renal insufficiency (P ¼ .004), lower actuarial survival
(log-rank P ¼ .0001), freedom from acute heart failure (P ¼ .002), and re-intervention (P ¼ .003). New
York Heart Association functional class IVat admission resulted in a higher incidence of low cardiac output state
(P<.0001), intra-aortic balloon pump (P ¼ .0001), prolonged ventilation (P<.0001), pneumonia (P ¼ .015),
and a lower actuarial freedom from re-intervention (P¼ .0001). Higher need for permanent pacemaker implan-
tation (P ¼ .015) and lower freedom from acute heart failure (P ¼ .019) emerged after urgencies/emergencies.
Conclusions: Redo aortic valve replacement procedures achieves good results, especially in nonendocarditic or
elective cases, and young or New York Heart Association functional class I/II patients. Indeed, endocarditis
significantly affects outcome. NewYork Heart Association functional class IVand nonelective procedures might
benefit from trans-catheter aortic valve-in-valve procedures. (J Thorac Cardiovasc Surg 2014;148:500-8)Supplemental material is available online.e Division of Cardiac Surgery, University of Verona Medical School, Verona,
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The Journal of Thoracic and Cardiovascular SurgAortic valve replacement (AVR) is the most frequently
employed cardiac valve operation, with more than 85,000
procedures performed yearly in the United States.1 With
the exponential growth of the geriatric population, the
need for redo AVR (RAVR) is similarly growing.2-4
Indeed, any redo cardiac surgery increases the risk of
mortality and morbidity when compared with the
corresponding first-time operation.2-7 However, the
extremely variable risk of mortality reported after RAVR
has been attributed to different factors related to the risk
profile of the enrolled population, the operator’s skill,
and the surgical volume of individual hospitals.2-7
Furthermore, the very high mortality rate reported in
some surgical experiences mandates identification ofery c August 2014
Abbreviations and Acronymns
AVR ¼ aortic valve replacement
EuroSCORE ¼ European System for Cardiac
Operative Risk Evaluation
NYHA ¼ New York Heart Association
RAVR ¼ redo aortic valve repair
TAVIV ¼ transcatheter aortic valve-in-valve
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Dpeculiar very–high-risk subgroups.2-7 On the other hand,
the fragile profile of the geriatric population has led in
past years to the widespread diffusion of transcatheter
aortic valve-in-valve (TAVIV) procedures, given a reported
relatively low risk of hospital mortality and morbidity.8,9
However, midterm and late outcome of TAVIV are still
unknown.8,9
Therefore, it was the aim of this study to analyze
in-hospital and long-term results of a consecutive series of
patients, and of specific high-risk subgroups, with at least
18 months of follow-up, undergoing RAVR during the
past 10 years at our large-volume institution, to serve as
benchmark for RAVR and to define subgroups in which
TAVIV may be better than surgery or contraindicated.METHODS
Scope and Data Collection
It was the aim of our study to evaluate the outcome of isolated RAVR or
RAVR plus cardiopulmonary artery bypass graft in patients considered
potentially eligible—in the current era—for TAVIV. Therefore, patients
with concomitant root or mitral valve diseasewere not enrolled in the study.
Accordingly, given the possibility for concomitant percutaneous coronary
intervention during TAVIV, patients undergoing RAVR with concomitant
coronary artery bypass graft were considered eligible for enrollment.
Accordingly, 131 consecutive RAVR (with or without concomitant
coronary artery bypass graft) patients admitted to our institution from
January 2002 to June 2011, with at least 18 months of follow-up, were
enrolled.
The choice to start enrollment from 2002 was done to avoid potential
biases related to differences in perioperative management and care, as
well as to have a picture of current RAVR practice at our institution.
Follow-up was closed on December 30, 2012; therefore, the choice to
truncate the enrollment at June 2011 was dictated by the intention to
evaluate at least midterm outcome at 18 months. No patient was lost during
follow-up, which was therefore 100% complete.
High-risk subgroups were chosen based on traditional risk factors for
hospital mortality according to the European System for Cardiac Operative
Risk Evaluation (EuroSCORE) score, as well as to worldwide accepted
literature data,1-4,10 provided that an acceptable sample size was at least
detected for each risk group in our population. Therefore, elderly
patients (aged >75 years), patients admitted in New York Heart
Association (NYHA) functional class IV, urgent/emergent procedures,
and endocarditic etiology were specifically analyzed. On the other hand,
to define patients at potential very–low-risk after RAVR, subgroups of
young patients (aged<65 years) and those admitted in NYHA functional
class I or II were specifically investigated in terms of long-term outcome.
All data were collected prospectively in the institutional database and
hospital charts but retrospectively analyzed. It was our institution’s policy
to discharge all patients to rehabilitation clinics; thus, follow-up started atThe Journal of Thoracic and Caour outpatient clinic at the end of the rehabilitation program, where patients
were followed-up with at least once. Events that occurred during
rehabilitation were collected from rehabilitation hospital charts and
follow-up was then continued by cardiac surgeons at the outpatient clinic
by the referral cardiologist or by the patient’s general practitioner after
the first surgical control. Follow-up data collection was based on patient
charts of our outpatient clinic, on telephone contacts with cardiologists
or general practitioners, and finally—in the absence of recent data—by
direct telephone contact with the patient. Institutional review board
approval and individual patient consent were waived due to the observa-
tional nature of the study.
Surgery
The choice for mechanical or biological prosthesis was left to patient
preference after discussion and evaluation with a surgeon regarding the
risks and benefits of each choice. Anesthesia, surgery, and cardiopulmo-
nary bypass were standardized and reported elsewhere.11 Preoperative
chest computed tomography was performed in all patients per institutional
policy, to correctly plan surgical re-entry. Surgical access consisted in a
median full re-sternotomy in all patients, and no ministernotomy or
alternative accesses were ever used during the study period. Peripheral
cannulation was chosen when surgical re-entry via median re-sternotomy
was considered high risk, but no percutaneous peripheral cannulation
was employed during the study period. Postoperative care was similarly
standardized and already reported.11
Definitions and Endpoints
Primary endpoints of the study were hospital mortality, which was
defined as all-cause mortality during the index hospitalization, and
follow-up mortality. The secondary endpoints were rate of hospital
complications, and follow-up freedom from acute heart failure,
reoperation, stroke, and thromboembolisms.11,12
The following hospital complications were collected: major cardiovas-
cular re-entry complications, defined as any severe and/or life-threatening
(ie, requiring reanimation and/or immediate changing of the surgical plan
and/or massive transfusions>4 red packed cells) injury of major vessels or
cardiac structures, occurred during surgical re-entry; revision for bleeding,
defined as any reoperation during the index hospitalization, due to
postoperative bleeding; need for permanent pacemaker implantation;
low cardiac output syndrome, defined as hemodynamic instability for
>1 hour during the intensive care unit stay, with peripheral signs of
hypoperfusion despite inotropic support and adequate correction of
preload, afterload, and all electrolyte and blood gas abnormalities11;
need for intraoperative/postoperative intra-aortic balloon pump; prolonged
intubation, defined as the need for prolonged (>48 hours) mechanical
ventilation or acute respiratory insufficiency after extubation with need
for reintubation or need for noninvasive ventilation lasting>48 hours11;
pneumonia, defined as evidence of bacterial growth in the lung with at least
1 positive bronchoalveolar fluid lavage culture, together with new alveolar
infiltrates at chest roentgenogram, irrespective of the presence of fever or
leukocytosis, or as evidence of new alveolar infiltrates with leukocytosis
and purulent sputum, confirmed by computed tomography scan and/or
by consultation of an independent infectivologist or pneumologist11;
stroke, defined per current guidelines12; and acute renal insufficiency,
defined as a>50% increase over the preoperative serum creatinine value.11
Other perioperative collected variables considered as surrogates of the
quality of clinical outcome were length of intubation (expressed in hours),
need for transfusions (regardless of red packed cells, fresh frozen plasma,
or platelets), and length of hospitalization (expressed in days, starting from
the day of surgery).
Apart from survival, other outcome variables collected during follow-up
were acute heart failure, defined as any episode of acute congestive heart
failure requiring hospitalization and/or optimization of medical therapy;
reintervention, defined as any reoperation on the aortic valve prosthesisrdiovascular Surgery c Volume 148, Number 2 501
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Dimplanted at the time of the indexed RAVR; stroke, as defined above; and
thromboembolisms, defined per current guidelines.12
Finally, when baseline characteristics were considered, urgent/emergent
operations were defined as operative procedures for life-threatening
conditions performed within 24 hours from hospital admission.
Statistical Analysis
Continuous variables are presented as mean  standard deviation, and
categorical variables are presented as absolute numbers and percentages.
Data were checked for normality before statistical analysis. Normally
distributed continuous variables were compared using the unpaired t test,
whereas the Mann-Whitney U test was used for non-normally distributed
variables. Categorical variables were analyzed using either the c2 test or
Fischer exact test as appropriate.
Due to the limited number of events at follow-up, a composite endpoint
of follow-up mortality and/or acute heart failure was considered. Because
of the intention to identify baseline characteristics predicting a high risk of
follow-up events after RAVR—to suggest alternative procedures to RAVR
(eg, transcatheter aortic valve replacement)—only preoperative variables
(including planned surgical intervention) were subjected to univariate
analysis for the composite endpoint. Variables with a P value of .10 or
less in the univariate analysis were consecutively subjected to a multivar-
iate logistic regression model to assess the independent influence of each
risk factor on the selected outcome. In detail, 6 preoperative/intraoperative
variables were selected to enter the multivariate model. A stepwise
(backward Wald) multivariable binary logistic regression analysis was
used. Both regression model discrimination and calibration were assessed
by using the C statistic for regression model discrimination and the
Hosmer-Lemeshow test statistic for model calibration. The models were
expressed in terms of adjusted odds ratio, 95% confidence interval, and
P value. Follow-up mortality and freedom from events were determined
with the method of Kaplan-Meier life table analysis. Log-rank test was
performed to ascertain between-groups differences. Statistical analysis
was performed by the SPSS program for Windows, version 13.0
(IBM-SPSS Inc, Armonk, NY).RESULTS
Preoperative and operative characteristics of 131 enrolled
patients are reported in Table E1. The proportion of
investigated high-risk subgroups were: 26.7% elderly
patients aged >75 years (35 patients), 15.3% patients
admitted in NYHA functional class IV (20 patients),
334.4% urgent/emergent priority admission patients
(45 patients), and 19.1% endocarditic etiology patients
(25 patients).Hospital and Follow-up Outcome in the Entire
Population
Hospital mortality was 2.3% (3 patients). The reported
rates of hospital complications were: major re-entry
complications 1.5%, revision for bleeding 9.2%, need for
permanent pacemaker 2.3%, low-output cardiac state
9.9%, intra-aortic counterpulsation (intra-aortic balloon
pump) 9.2%, stroke 3.1%, prolonged ventilation 18.3%,
pneumonia 4.6%, acute renal insufficiency 11.5%,
renal replacement therapy 4.6%, and need for transfusions
60.3%. Mean follow-up was 55.1  32.4 months. Ten-year
survival was 61.5%  8.6%. Ten-year freedom from acute
heart failure, reoperations, stroke, and thromboembolisms502 The Journal of Thoracic and Cardiovascular Surgwere 62.9%  6.9%, 97.8%  1.5%, 93.2%  3.0%,
and 91.2%  3.2%, respectively (Figure 1).
Hospital and Follow-up Outcome in Subgroups at
Higher Risk
When elderly patients were considered, hospital mortal-
ity and complications proved comparable to those of
younger patients, although rough data indicate a slightly
worse hospital outcome in the aged population (Table 1).
An obvious lower (although not statistically significant)
follow-up survival was detected (patients aged>75 years
52.5%  11.3% vs patients aged <75 years 67.4% 
9.3%; P ¼ .168). Follow-up freedom from acute heart fail-
ure (patients aged>75 years 71.1%  10.0% vs patients
aged<75 years 61.7%  7.9%; P ¼ .601), reoperation
(patients aged >75 years 100.0% vs patients aged
<75 years 96.9%  2.2%; P ¼ .367), stroke (patients
aged>75 years 90.9%  8.7% vs patients aged<75 years
93.5%  3.0%; P ¼ .581) and thromboembolism (patients
aged>75 years 88.3%  8.8% vs patients aged<75 years
91.7% 3.4%; P¼ .898) proved similar, regardless of age.
However, when young patients (aged <65 years) were
analyzed, a particularly favorable long-term outcome
was identified, with a 77.9%  6.7% 10-year survival,
70.1%  5.8% freedom from acute heart failure, 96.7%
 3.3% freedom from reoperation, 90.8%  4.8%
freedom from stroke, and 93.3%  4.8% freedom from
thromboembolisms.
When stratified by NYHA functional class, patients
admitted in NYHA functional class IV showed a similar
hospital mortality (5.0% vs NYHA class<IV ¼ 1.8%),
but also a significantly higher incidence of postoperative
low cardiac output syndrome, need for intra-aortic balloon
pump, prolonged intubation, and pneumonia (Table 1).
When follow-up outcome was considered, survival proved
comparable (NYHA class IV ¼ 62.2%  11.7% vs
NYHA class<IV 60.3%  10.6%; P ¼ .159), as well as
stroke (Figure 2, C), and thromboembolism (Figure 2, D),
whereas a lower but not significant freedom from acute
heart failure was reported (Figure 2, A). Only freedom
from reoperation was significantly lower in patients
admitted with NYHA functional class IV (P < .0001)
(Figure 2, B). On the other hand, NYHA functional class I
or II at admission identifies a subgroup of patients with
an excellent follow-up outcome, given the reported
85.8%  7.8% 10-year survival, 89.8%  5.8%
freedom from acute heart failure, 100% freedom from
reintervention, 97.5%  2.5% freedom from stroke, and
94.0%  4.2% freedom from thromboembolisms.
When priority at admission was considered, those
referred as emergent/urgent patients showed a comparable
hospital outcome compared to elective cases, with the
only exception being a higher need for permanent
pacemaker implantation in the urgencies/emergenciesery c August 2014
FIGURE 1. Ten-year actuarial freedom from (A) acute heart failure, (B) reoperations, (C) stroke, and (D) thromboembolisms.
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not statistically significant in nonelective procedures
(emergent/urgent 47.8%  12.8% vs elective 66.8% 
10.0%; P ¼ .211). However, freedom from acute heart
failure was significantly lower in urgent/emergent patients
(54.5%  10.0% vs elective 68.8%  8.8%; P ¼ .019)
(Figure 3, A), whereas freedom from reoperation, stroke,
and thromboembolism were similar between the 2 groups
(Figure 3, B-D).
Finally, when the endocarditic etiology was considered, a
significantly higher hospital mortality, prevalence of
postoperative low cardiac output state and need for intra-
aortic balloon pump, presence of prolonged intubation
and pneumonia, as well as of acute renal insufficiency
were found in this cohort (Table 1). The other hospital
outcome variables proved similar between the endocarditic
and the nonendocarditic etiology (Table 1). Follow-up
outcome was similarly worse for endocarditis, given the
lower survival (20.6%  9.7% vs nonendocarditis 75.1%
 12.0%; P< .0001), freedom from acute heart failure
(P ¼ .002) (Figure 4, A), and freedom from reoperation
(P ¼ .003) (Figure 4, B). However, freedom from strokeThe Journal of Thoracic and Caand thromboembolism were similar (Figure 4, C and D,
respectively). On the other hand, the absence of endocardi-
tis at RAVR identifies a subset of patients with a particularly
favorable follow-up outcome (75.1%  12.0% 10-year
survival, 67.7%  7.6% freedom from acute heart failure,
100% freedom from reintervention, 90.9%  8.7%
freedom from stroke, and 86.4%  9.4% freedom from
thromboembolisms).
Predictors of Composite Endpoint of Follow-up
Mortality/Acute Heart Failure
The following preoperative and intraoperative variables
were significantly associated with the composite endpoint
of follow-up mortality/acute heart failure at univariate
analysis: EuroSCORE (P ¼ .0001), age (P ¼ .04), NYHA
functional class at admission (P ¼ .0001), endocarditis
(P< .0001), major arrhythmias at admission (P ¼ .02),
and planned surgical intervention (P ¼ .02). Of these,
independent predictors of the composite endpoint of
follow-up mortality/acute heart failure were EuroSCORE
(odds ratio [OR] ¼ 1.3; 95% confidence interval [CI],
1.0-1.7; P ¼ .04), NYHA functional class at admissionrdiovascular Surgery c Volume 148, Number 2 503
TABLE 1. Hospital outcome in subgroups at risk
Variable
Age
>75 y
(n ¼ 35)
Age
<75 y
(n ¼ 96) P
NYHA
class IV
(n ¼ 20)
NYHA
class I-III
(n ¼ 111) P
Urgent/
Emergent
(n ¼ 45)
Elective
(n ¼ 86) P
Endocarditis
(n ¼ 25)
No
Endocarditis
(n ¼ 106) P
Mortality 2.9 (1) 2.1 (2) .793 5.0 (1) 1.8 (2) .379 2.2 (1) 2.3 (2) .970 8.0 (2) 0.9 (1) .034
Major cardiovascular
re-entry complications
2.9 (1) 1.0 (1) .453 0 () 1.8 (2) .545 2.2 (1) 1.2 (1) .639 4.0 (1) 0.9 (1) .262
Revision for bleeding 11.4 (4) 8.3 (8) .587 15.0 (3) 8.1 (9) .325 11.1 (5) 8.1 (7) .576 16.0 (4) 7.5 (8) .188
Need for permanent
pacemaker
5.7 (2) 1.0 (1) .114 0 () 2.7 (3) .457 6.7 (3) 0 () .015 4.0 (1) 1.9 (2) .525
Low cardiac output state 11.4 (4) 9.4 (9) .728 40.0 (8) 4.5 (5) <.001 11.1 (5) 9.3 (8) .742 32.0 (8) 4.7 (5) <.001
Intraoperative/postoperative
intra-aortic balloon pump
8.6 (3) 9.4 (9) .888 35.0 (7) 4.5 (5) <.001 11.1 (5) 8.1 (7) .576 32.0 (8) 3.8 (4) <.001
Prolonged intubation (>48 h) 14.3 (5) 19.8 (19) .471 60.0 (12) 10.8 (12) <.001 20.0 (9) 17.4 (15) .719 36.0 (9) 14.2 (15) .011
Pneumonia 8.6 (3) 3.1 (3) .187 15.0 (3) 2.7 (3) .015 6.7 (3) 3.5 (3) .409 12.0 (3) 2.8 (3) .049
Stroke 2.9 (1) 3.1 (3) .937 5.0 (1) 2.7 (3) .583 0 (0) 4.7 (4) .142 4.0 (1) 2.8 (3) .760
Acute renal insufficiency 11.4 (4) 11.5 (11) .996 20.0 (4) 9.9 (11) .192 13.3 (6) 10.5 (9) .624 28.0 (7) 7.5 (8) .004
Length of intubation, h 40.8  89.9 23.3  43.5 .227 42.8 107.8 25.6  47.7 .344 28.1  51.6 28.1  64.2 .998 10.4  8.1 29.3  61.7 .499
Transfused patients 65.7 (23) 58.3 (56) .445 70.0 (14) 58.6 (65) .336 68.9 (31) 55.8 (48) .146 68.0 (17) 58.5 (62) .382
Length of hospitalization, d 12.1  5.9 12.5  7.1 .770 12.3  4.8 12.4  7.0 .947 12.6  5.5 12.3  7.4 .797 10.5  2.4 12.5  7.0 .414
Values are presented as mean  standard deviation or% (n). NYHA, New York Heart Association.
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etiology (OR ¼ 18.0; 95% CI, 4.6-61.2; P ¼ .0001).
The discrimination C statistic for the final logistic
regression analysis was .79. The c2 test result for the
Hosmer-Lemeshow goodness of fit test was 6.7 for an
overall c2 significance of .680.
DISCUSSION
The current widespread use of transthoracic AVR,
together with a reported high risk of perioperative mortality
and major complications in redo aortic valve surgery, has
led to an exponential use of transthoracic AVR technology
for patients with aortic prosthetic dysfunction.9,13 In
particular, some comorbid conditions and advanced age
have been emphasized as preferential indications for
TAVIV.9,13 On the other hand, current RAVR outcomes
are a poorly addressed issue in the literature due to the
fact that current reports of RAVR involve a case-mixed
population of patients.3,4,6,7 Other studies focusing on the
detrimental prognostic role of endocarditis on long-term
outcome after RAVR have similarly reported very
poor surgical results,10 although endocarditis is still a
well-defined contraindication to TAVIV. Nevertheless,
application of transthoracic AVR has been recently reported
even in patients with active endocarditis.14 Furthermore,
some other literature studies on TAVIV reported only
early or short-term outcome15,16 or a limited number of
patients.13,15 Therefore, the literature lacks studies
addressing the long-term outcome of RAVR in a significant
number of patients potentially eligible today for TAVIV
procedure, and the relative roles of TAVIV and RAVR in
that scenario.
We were able to show acceptable results, provided that
endocarditic etiology is not reported. In particular, we found504 The Journal of Thoracic and Cardiovascular Surghospital mortality as low as 2.3%, which was also signifi-
cantly lower than what was predicted by our patient-
specific preoperative EuroSCORE. Despite the fact that
no direct comparison with TAVIV was considered in this
study due to the lack of concomitant TAVIV experience at
our institution, TAVIV has been reported to achieve a 0%
hospital mortality in some centers,13 but also a 14% to
25% postoperative mortality in other experiences.17,18
Overall, a volume-related effect on outcome after TAVIV
has been emphasized by recent studies, with results
ranging from 100% to 66%.13 For example, Piazza and
colleagues19 reported an 88.0% procedural success with
Sapien valves (Edwards Lifesciences, Irvine, Calif) and a
10% 30-day mortality. Seiffert and colleagues18 reported
a 25% 30-day mortality in 4 patients undergoing TAVIV.
It should be emphasized that all these reports demonstrated
excellent early results with TAVIV in patients unsuitable for
traditional surgical RAVR.13,18,19
On the other hand, a recent Canadian experience on a
very large number of case-mixed cardiac redo surgical pro-
cedures reported an overall hospital mortality<6%, further
reduced to 4% in isolated RAVR, and concluded that more
favorable results than what currently predicted by risk
scores can be expected.4 Our data confirm those studies3,4
showing excellent results in terms of hospital mortality
after RAVR, provided that endocarditis was not present,14
with EuroSCORE similarly affecting long-term rather
than hospital mortality in our experience. Indeed, Euro-
SCORE proved to be an independent determinant of the
composite endpoint of follow-up death and acute heart fail-
ure in our study.
When subgroups at higher risk were considered, it was
noteworthy that elderly patients older than age>75 years
demonstrated similar in-hospital and long-term outcomesery c August 2014
FIGURE 2. Ten-year actuarial freedom from (A) acute heart failure, (B) reoperations, (C) stroke, and (D) thromboembolisms in New York Heart
Association class IV patients.
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cardiac surgery can be safely done in the last decades of
life.20 Our data also supported the concept that EuroSCORE
overestimates hospital mortality in aortic valve surgery,21
particularly in elderly patients.20 On the other hand,
young patients aged<65 years showed a remarkably good
long-term outcome in terms of survival and acute heart fail-
ure, superior in terms of absolute numbers—although not
statistically significant—to that of elderly patients, thus
supporting the preferential need for conventional RAVR
in this subset of patients, especially with the current absence
of long-term data after TAVIV.
When patients admitted in NYHA functional class IVand
urgent/emergent indication were considered, a doubled
hospital mortality, and a significantly higher incidence of
low cardiac output syndrome, need for intra-aortic balloon
pump, prolonged ventilation, and the related consequent
higher incidence of pneumonia, were detected in NYHA
functional class IV, suggesting the potential for a better
outcome with TAVIV in this high-risk cohort, as early as
during hospitalization. Accordingly, NYHA functionalThe Journal of Thoracic and Caclass at admission proved to be an independent predictor
of the composite endpoint of death and/or acute heart
failure at long-term follow-up. NYHA functional class is
a well-recognized risk factor in both EuroSCORE and
Society of Thoracic Surgeons score: A recent analysis
identified a 10-fold higher hospital mortality, but similar
long-term survival, in patients admitted in NYHA func-
tional class III/IV.22 Our data confirm either worse
hospital outcome or overall satisfactory long-term
prognosis in NYHA functional class IV hospital
survivors.22 Moreover, our study demonstrated that
NYHA functional class I and II at admission identifies a
subgroup of patients with remarkably good early and
long-term outcomes. Our data suggest that alternative
procedures to surgery should not be indicated in that
peculiar cohort of patients, given the excellent outcome
with conventional surgery.
Emergent/urgent procedures showed a significantly
higher need for postprocedural permanent pacemaker
implantation only early after surgery. Unstable he-
modynamics, hemodynamic compromise and activerdiovascular Surgery c Volume 148, Number 2 505
FIGURE 3. Ten-year actuarial freedom from (A) acute heart failure, (B) reoperations, (C) stroke, and (D) thromboembolisms in urgent/emergent
procedures.
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emergent indications to surgery and are contempo-
rarily responsible for the development of a complete
atrioventricular block, mandating need for permanent
pacemaker implantation. It has been demonstrated
that pulmonary hypertension and intraoperative/post-
operative cardiac arrest—all proxy variables of cardiac
decompensation and unstable hemodynamics—predicted
the need for permanent pacemaker after aortic valve
replacement.23 Furthermore, cumbersome endocarditic
procedures—extending deep in the annulus and involving
the conduction system—may also help to explain these
findings.23,24 Furthermore, the profound affect of
endocarditis on emergent/urgent procedures, observed
also in our experience, help to explain the higher acute
heart failure at follow-up in these patients,10,25
supporting the hypothesis of a potentially better outcome
after TAVIV in patients with nonelective priority.
Certainly future studies on TAVIV practice with long-
term data in these peculiar subgroups of patients are
needed before definitive conclusions.506 The Journal of Thoracic and Cardiovascular SurgFinally, our data confirm the already reported poor
outcome for prosthetic endocarditis,10,25 which also proves
as independent predictor of long-term mortality (the stron-
gest predictor) and acute heart failure in our experience.
Leontyev and colleagues10 have recently reported a
significantly worse baseline profile, more technically
demanding operations, worse hospital outcome (low output
state, need for intra-aortic balloon pump, renal failure, and
mortality), together with significantly lower 1-year (52%)
to 10-year (31%) survival, and an overall 5-year freedom
from recurrences of 80% in endocarditis.10 Romano and
colleagues25 reported 24% hospital mortality and 33%
10-year survival in prosthetic endocarditis. Similarly,
endocarditis was the strongest predictor of the composite
endpoint of follow-up death/acute heart failure in our
population. Opposite to that, another interesting finding of
our endocarditic-related subanalysis stem from the
excellent results achieved by nonendocarditis patients,
who demonstrated<1% hospital mortality, rare periproce-
dural complications, 75% survival, 100% freedom from
reoperation, and 93% freedom from stroke at 10 years,ery c August 2014
FIGURE 4. Ten-year actuarial freedom from (A) acute heart failure, (B) reoperations, (C) stroke, and (D) thromboembolisms in endocarditis.
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eligible for transcatheter aortic valve replacement. There-
fore, despite endocarditis is obviously an absolute indication
to surgery, also the absence of endocarditis can be useful for
risk prediction, because it anticipates a good hospital and
long-term follow-up outcome, especially if patients with
low NYHA functional class or elective indication are
considered. In our opinion, these patients should be first
considered for surgery, rather than alternative procedures.Limitations of the Study
The main limitation of our study is related to the
single-center retrospective design. However, the literature
lacks studies investigating current trends in RAVR in
patients with long-term outcome data, without excessive
case mix (eg, root procedures and concomitant mitral
disease). Furthermore, the reported cohort of patients
comprised also patients with endocarditis and with
mechanical AVR at the time of the first operation who
were not amenable to TAVR, so we decided to review our
overall experience of RAVR to avoid selection bias and toThe Journal of Thoracic and Careport current results of all-comers undergoing RAVR
at our institution during the past 11 years with at least
18-month follow-up. Another limitation is related to the
absence of a direct comparison with a contemporary cohort
of TAVIV patients; however, TAVIV is not the standard of
care in our institution, and it is actually limited to a few
patients judged to be contraindicated to RAVR by the local
heart team. Furthermore, TAVIV is an extremely recent
practice, thus no long-term data are available in the
literature.CONCLUSIONS
There is an urgent need for direct comparisons between
RAVR and TAVIV in the literature, with both randomized
controlled trials and observational registries. At the same
time, a note of caution seems necessary for TAVIV
procedures in the absence of long-term results.References
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TABLE E1. Preoperative and operative characteristics of patients
Characteristic Result
Age, y 65.6  12.9
European System for Cardiac Operative Risk Evaluation
score (additive)
8.2  1.9
Women 32.8 (43)
Chronic obstructive pulmonary disease 9.2 (12)
Left ventricular ejection fraction (Simpson method),% 51.8  10.5
Previous aortic valve prosthesis
Mechanical 19.1 (25)
Biological 80.9 (106)
Type of intervention
Redo aortic valve replacement 75.5 (99)
Redo aortic valve replacement þ coronary artery
bypass graft
24.5 (32)
Type of prosthesis
Biologic 65.6 (86)
Mechanical 29.0 (38)
Homograft 5.3 (7)
Aortic crossclamp time, min 104.0  50.4
Cardiopulmonary bypass time, min 147.3  72.7
Values are presented as mean  standard deviation or% (n).
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